[SCHEDULE 13G] Royalty Pharma plc SEC Filing
Capital International Investors reports beneficial ownership of 23,111,998 shares of Royalty Pharma plc, representing 5.5% of the approximately 421,370,657 shares believed outstanding. CII is deemed the beneficial owner through its investment management entities and holds sole voting power for 23,006,820 shares and sole dispositive power for 23,111,998 shares. The filing is a Schedule 13G and the reporting person is classified as an investment adviser (IA). The statement certifies the position is held in the ordinary course of business and was not acquired to change or influence control of the issuer.
Capital International Investors segnala la titolarit脿 effettiva di 23,111,998 azioni di Royalty Pharma plc, pari al 5.5% delle circa 421,370,657 azioni ritenute in circolazione. CII 猫 considerata titolare effettiva attraverso le sue entit脿 di gestione degli investimenti e detiene la piena facolt脿 di voto su 23,006,820 azioni e la piena facolt脿 dispositiva su 23,111,998 azioni. Il deposito 猫 un Schedule 13G e la persona che presenta la segnalazione 猫 classificata come consulente per gli investimenti (IA). La dichiarazione certifica che la posizione 猫 detenuta nell'ordinaria gestione d'impresa e non 猫 stata acquisita per modificare o influenzare il controllo dell'emittente.
Capital International Investors informa la titularidad beneficiaria de 23,111,998 acciones de Royalty Pharma plc, que representan el 5.5% de las aproximadamente 421,370,657 acciones estimadas en circulaci贸n. CII se considera beneficiaria a trav茅s de sus entidades de gesti贸n de inversiones y posee poder de voto exclusivo sobre 23,006,820 acciones y poder dispositivo exclusivo sobre 23,111,998 acciones. El documento presentado es un Schedule 13G y la persona informante est谩 clasificada como asesor de inversiones (IA). La declaraci贸n certifica que la posici贸n se mantiene en el curso ordinario del negocio y no se adquiri贸 para cambiar o influir en el control del emisor.
Capital International Investors電� Royalty Pharma plc鞚� 23,111,998欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頃╇媹雼�. 鞚措姅 鞎� 421,370,657欤�搿� 於旍爼霅橂姅 鞙犿喌欤检嫕鞚� 5.5%鞐� 頃措嫻頃╇媹雼�. CII電� 韴瀽 鞖挫毄 氩曥澑鞚� 韱淀暣 鞁れ鞝� 靻岇湢鞛愲 臧勳＜霅橂┌, 23,006,820欤检棎 雽�頃� 雼弲 鞚橁舶甓�瓿� 23,111,998欤检棎 雽�頃� 雼弲 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖 靹滊電� Schedule 13G鞚措┌ 氤搓碃鞚胳潃 韴瀽 鞛愲鞐呾瀽(IA)搿� 攵勲霅╇媹雼�. 頃措嫻 歆勳垹鞚� 鞚� 歆�攵勳澊 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅� 瓴冹澊氅� 氚滍枆靷潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃╇媹雼�.
Capital International Investors d茅clare d茅tenir effectivement 23,111,998 actions de Royalty Pharma plc, soit 5.5% des quelque 421,370,657 actions estim茅es en circulation. CII est r茅put茅e propri茅taire effectif via ses entit茅s de gestion d'investissements et d茅tient la puissance de vote exclusive sur 23,006,820 actions et la puissance de disposition exclusive sur 23,111,998 actions. Le d茅p么t est un Schedule 13G et la personne d茅clarante est class茅e comme conseiller en investissements (IA). La d茅claration certifie que la position est d茅tenue dans le cadre normal des activit茅s et n'a pas 茅t茅 acquise pour modifier ou influencer le contr么le de l'茅metteur.
Capital International Investors meldet die wirtschaftliche Eigent眉merschaft an 23,111,998 Aktien von Royalty Pharma plc, was 5.5% der gesch盲tzt rund 421,370,657 ausstehenden Aktien entspricht. CII gilt 眉ber seine Investment-Management-Einheiten als wirtschaftlicher Eigent眉mer und h盲lt alleinige Stimmrechte f眉r 23,006,820 Aktien sowie alleinige Verf眉gungsgewalt 眉ber 23,111,998 Aktien. Die Einreichung erfolgt als Schedule 13G und die meldende Person ist als Investmentberater (IA) klassifiziert. Die Erkl盲rung best盲tigt, dass die Position im normalen Gesch盲ftsablauf gehalten wird und nicht erworben wurde, um die Kontrolle des Emittenten zu ver盲ndern oder zu beeinflussen.
- Institutional ownership of 23,111,998 shares (5.5% of the class)
- Sole voting power for 23,006,820 shares and sole dispositive power for 23,111,998 shares
- None.
Insights
TL;DR: A material institutional passive stake of 5.5% is disclosed, confirming substantial ownership without intent to seek control.
Capital International Investors' Schedule 13G discloses beneficial ownership of 23,111,998 shares (5.5%) of Royalty Pharma. For investors, the scale of the position is noteworthy because a >5% holding by a large asset manager signals meaningful institutional interest. The filing also shows near-complete alignment between voting and dispositive power, with 23,006,820 shares under sole voting control and 23,111,998 shares under sole dispositive control.
The certification that the shares are held in the ordinary course and not to influence control frames this as a passive, portfolio stake rather than an activist position.
TL;DR: Schedule 13G classification and the certification indicate a passive investor profile, not a control-seeking approach.
The filing classifies the reporting person as an investment adviser (IA) and is submitted on Schedule 13G, consistent with passive institutional ownership disclosures. The explicit certification in the filing states the securities "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer," which reduces immediate governance concerns about an active campaign.
From a governance perspective, the record shows significant ownership that could matter in future votes, but no present indication of coordination or intent to alter control.
Capital International Investors segnala la titolarit脿 effettiva di 23,111,998 azioni di Royalty Pharma plc, pari al 5.5% delle circa 421,370,657 azioni ritenute in circolazione. CII 猫 considerata titolare effettiva attraverso le sue entit脿 di gestione degli investimenti e detiene la piena facolt脿 di voto su 23,006,820 azioni e la piena facolt脿 dispositiva su 23,111,998 azioni. Il deposito 猫 un Schedule 13G e la persona che presenta la segnalazione 猫 classificata come consulente per gli investimenti (IA). La dichiarazione certifica che la posizione 猫 detenuta nell'ordinaria gestione d'impresa e non 猫 stata acquisita per modificare o influenzare il controllo dell'emittente.
Capital International Investors informa la titularidad beneficiaria de 23,111,998 acciones de Royalty Pharma plc, que representan el 5.5% de las aproximadamente 421,370,657 acciones estimadas en circulaci贸n. CII se considera beneficiaria a trav茅s de sus entidades de gesti贸n de inversiones y posee poder de voto exclusivo sobre 23,006,820 acciones y poder dispositivo exclusivo sobre 23,111,998 acciones. El documento presentado es un Schedule 13G y la persona informante est谩 clasificada como asesor de inversiones (IA). La declaraci贸n certifica que la posici贸n se mantiene en el curso ordinario del negocio y no se adquiri贸 para cambiar o influir en el control del emisor.
Capital International Investors電� Royalty Pharma plc鞚� 23,111,998欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨潓鞚� 氤搓碃頃╇媹雼�. 鞚措姅 鞎� 421,370,657欤�搿� 於旍爼霅橂姅 鞙犿喌欤检嫕鞚� 5.5%鞐� 頃措嫻頃╇媹雼�. CII電� 韴瀽 鞖挫毄 氩曥澑鞚� 韱淀暣 鞁れ鞝� 靻岇湢鞛愲 臧勳＜霅橂┌, 23,006,820欤检棎 雽�頃� 雼弲 鞚橁舶甓�瓿� 23,111,998欤检棎 雽�頃� 雼弲 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖 靹滊電� Schedule 13G鞚措┌ 氤搓碃鞚胳潃 韴瀽 鞛愲鞐呾瀽(IA)搿� 攵勲霅╇媹雼�. 頃措嫻 歆勳垹鞚� 鞚� 歆�攵勳澊 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅� 瓴冹澊氅� 氚滍枆靷潣 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 鞚胳頃╇媹雼�.
Capital International Investors d茅clare d茅tenir effectivement 23,111,998 actions de Royalty Pharma plc, soit 5.5% des quelque 421,370,657 actions estim茅es en circulation. CII est r茅put茅e propri茅taire effectif via ses entit茅s de gestion d'investissements et d茅tient la puissance de vote exclusive sur 23,006,820 actions et la puissance de disposition exclusive sur 23,111,998 actions. Le d茅p么t est un Schedule 13G et la personne d茅clarante est class茅e comme conseiller en investissements (IA). La d茅claration certifie que la position est d茅tenue dans le cadre normal des activit茅s et n'a pas 茅t茅 acquise pour modifier ou influencer le contr么le de l'茅metteur.
Capital International Investors meldet die wirtschaftliche Eigent眉merschaft an 23,111,998 Aktien von Royalty Pharma plc, was 5.5% der gesch盲tzt rund 421,370,657 ausstehenden Aktien entspricht. CII gilt 眉ber seine Investment-Management-Einheiten als wirtschaftlicher Eigent眉mer und h盲lt alleinige Stimmrechte f眉r 23,006,820 Aktien sowie alleinige Verf眉gungsgewalt 眉ber 23,111,998 Aktien. Die Einreichung erfolgt als Schedule 13G und die meldende Person ist als Investmentberater (IA) klassifiziert. Die Erkl盲rung best盲tigt, dass die Position im normalen Gesch盲ftsablauf gehalten wird und nicht erworben wurde, um die Kontrolle des Emittenten zu ver盲ndern oder zu beeinflussen.
FAQ
How many RPRX shares does Capital International Investors beneficially own?
What voting and dispositive powers does CII hold over RPRX shares?
What type of SEC filing did Capital International Investors submit for RPRX?
Is this stake intended to change or influence control of Royalty Pharma (RPRX)?
What is the date of the event that required this Schedule 13G filing?
